29921-51-5

Basic information

• Product Name: 2-Hydroxy-8-iodonaphthalene
• Synonyms: 2-Hydroxy-8-iodonaphthalene;1-Naphthalenecarbonitrile, 7-hydroxy-;2-Naphthalenol, 8-iodo-;8-iodo-2-Naphthalenol;8-Iodo-naphthalen-2-ol
• CAS NO: 29921-51-5
• Molecular Formula: C₁₀H₇IO
• Molecular Weight: 270.06645
• Mol File: 29921-51-5.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 376.9±15.0 °C(Predicted)
• Appearance: /
• Density: 1.874±0.06 g/cm3(Predicted)
• PKA: 9.12±0.40(Predicted)
• CAS DataBase Reference: 2-Hydroxy-8-iodonaphthalene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxy-8-iodonaphthalene(29921-51-5)
• EPA Substance Registry System: 2-Hydroxy-8-iodonaphthalene(29921-51-5)

Safety Data

• Hazardous Substances Data: 29921-51-5(Hazardous Substances Data)

Usage

General Description

2-Hydroxy-8-iodonaphthalene is a chemical compound with the molecular formula C10H7IO. It is an aromatic compound with a hydroxy group and an iodine atom attached to a naphthalene ring. 2-Hydroxy-8-iodonaphthalene is used as a reagent in organic synthesis and as a precursor for the production of various organic compounds. It is also used in the manufacturing of dyes, pharmaceuticals, and agrochemicals. 2-Hydroxy-8-iodonaphthalene is a solid at room temperature and is soluble in organic solvents such as ether and chloroform. It should be handled and stored with proper safety measures in place due to its potentially hazardous nature.

Upstream product

• 118-46-7 8-amino-2-naphthol 
• 28547-28-6 2-bromo-4-hydroxybenzoic acid 
• 7681-11-0 potassium iodide 

Downstream Products

• 92287-47-3 8-methoxy-2-naphthylamine 
• 66240-21-9 1-iodo-7-methoxynaphthalene 
• 138112-76-2 agomelatine 
• 138113-09-4 2-(7-methoxynaphth-1-yl)ethylamine 
• 158365-54-9 1-cyano-7-methoxynaphthalene 
• 849109-71-3 7-benzyloxy-1-iodo-naphthalene 

Relevant articles and documents

Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes

A novel series of pyridones were discovered as potent EP3 antagonists. Optimization guided by EP3 binding and functional assays as well as by eADME and PK profiling led to multiple compounds with good physical properties, excellent oral bioavailability, and a clean in vitro safety profile. Compound 13 was identified as a lead compound as evidenced by the reversal of sulprostone-induced suppression of glucose-stimulated insulin secretion in INS 1E β-cells in vitro and in a rat ivGTT model in vivo. A glutathione adduction liability was eliminated by replacing the naphthalene of structure 13 with the indazole ring of structure 43.

Antracene derivatives having heteroaryl substituted naphthyl group and organic light-emitting diode including the same

An anthracene derivative represented by the following [Chemical Formula A] and an organic light emitting device including the same are provided X. 1 To X7 , Y and Z are as defined by the description of the invention. [Formula A] (by machine translation)

Asymmetric antracene derivatives having two naphthyl groups and organic light-emitting diode including the same

The present invention relates to an antracene derivative represented by the following [Formula A] or [Formula B], and an organic light-emitting diode including the same. Substituents X_1 to X_7 , Y, and Z are the same as defined in the detailed description of the invention.